Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.57 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29589153 | 1.00 | POLB (0.72) | POLBALDH1A1NPFFR1NPFFR2CYP1A2 | |
| SCHEMBL3648083 | 0.84 | LMNA (0.72) | POLBALDH1A1NPFFR1NPFFR2CYP1A2 | |
| SCHEMBL2538783 | 0.84 | KDM4E (0.66) | POLBALDH1A1NPFFR1NPFFR2EGFR | |
| SCHEMBL6492060 | 0.84 | POLB (1.00) | POLBALDH1A1CYP1A2NR4A2MEN1 | |
| SCHEMBL6481363 | 0.81 | POLB (0.53) | POLBALDH1A1NPFFR1NPFFR2CYP1A2 | |
| SCHEMBL4748554 | 0.81 | POLB (0.53) | POLBALDH1A1NPFFR1NPFFR2NR4A2 | |
| SCHEMBL440491 | 0.81 | NR4A2 (0.74) | POLBALDH1A1NR4A2MEN1KMT2A | |
| SCHEMBL20867715 | 0.79 | ALDH1A1 (0.57) | POLBALDH1A1NPFFR1NPFFR2EGFR | |
| SCHEMBL3531515 | 0.79 | LMNA (0.66) | POLBALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL26632753 | 0.78 | POLB (0.50) | POLBALDH1A1NPFFR1NPFFR2NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380741-B | Preparation method of 4-position alkylated derivative of 2-methylquinoline compound | 济南大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-114380741-A | Preparation method of 4-position alkylated derivative of 2-methylquinoline compound | 济南大学 | 2022-04-22 | — | — | CN | disclosed |
| EP-2922845-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-9249102-B2 | Anthelmintic compounds and compositions and method of using thereof | MERIAL, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249102-B2 | Anthelmintic compounds and compositions and method of using thereof | MERIAL, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| EP-1373199-A4 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1373199-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | Bristol-Myers Squibb Pharma Company (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | CYP3A5, ABCC5, CXXC5 | POLB 4289/4885ALDH1A1 2176/4885NPFFR1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.